Metcela Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $14M

  • Investors
  • 22

Metcela General Information

Description

Developer of a regenerative medicine therapy designed to treat congenital heart disease and rare conditions. The company offers innovative cell-based pharmaceuticals developed through advanced research in cardiac regeneration, enabling pediatric and rare disease patients to access transformative treatments that restore heart function and improve quality of life.

Contact Information

Website
www.metcela.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3-25-22 Tonomachi
  • Kawasaki-ku, Kanagawa
  • Kawasaki, Kanagawa 210-0821
  • Japan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 3-25-22 Tonomachi
  • Kawasaki-ku, Kanagawa
  • Kawasaki, Kanagawa 210-0821
  • Japan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Metcela Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC (Series C) 28-Jun-2022 $14M Completed Pre-Clinical Trials
11. Later Stage VC (Series B) 24-Feb-2021 Completed Pre-Clinical Trials
10. Accelerator/Incubator 08-Jul-2019 Completed Pre-Clinical Trials
9. Early Stage VC (Series A) 30-Aug-2018 Completed Pre-Clinical Trials
8. Grant 01-Jul-2018 Completed Pre-Clinical Trials
7. Accelerator/Incubator 01-Jan-2018 Completed Pre-Clinical Trials
6. Accelerator/Incubator 01-Jan-2018 Completed Pre-Clinical Trials
5. Grant 01-Mar-2017 Completed Pre-Clinical Trials
4. Accelerator/Incubator 01-Jan-2017 $1.37M Completed Pre-Clinical Trials
3. Accelerator/Incubator $1.37M Completed Pre-Clinical Trials
To view Metcela’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Metcela Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a regenerative medicine therapy designed to treat congenital heart disease and rare conditions. The company
Drug Discovery
Kawasaki, Japan
20 As of 2025

Plymouth Meeting, PA
 

Mont-Saint-Guibert, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Metcela Competitors (43)

One of Metcela’s 43 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Cellaion Formerly VC-backed Mont-Saint-Guibert, Belgium
WaVe Life Sciences Formerly VC-backed Cambridge, MA
Skyhawk Therapeutics Venture Capital-Backed Waltham, MA
Cardurion Venture Capital-Backed Burlington, MA
You’re viewing 5 of 43 competitors. Get the full list »

Metcela Patents

Metcela Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4671364-A1 Cell population containing cardiac stem cells Pending 24-Feb-2023
JP-2024120546-A Cell population containing cardiac stem cells Active 24-Feb-2023
WO-2024176514-A1 Cell population containing cardiac stem cells Inactive 24-Feb-2023
JP-7373246-B1 Cell populations including cardiac stem cells Active 24-Feb-2023
CA-3226199-A1 Fibroblast-containing pharmaceutical composition for treating kidney disease Pending 08-Sep-2021 A61K35/33
To view Metcela’s complete patent history, request access »

Metcela Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Metcela Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cyberdyne Corporation Minority
Reazon Capital Venture Capital Minority
Reazon Holdings Holding Company Minority
TOHOKU University Venture Partners Venture Capital Minority
Alfresa Holdings Corporation Minority
You’re viewing 5 of 22 investors. Get the full list »

Metcela Acquisitions (1)

Metcela’s most recent deal was a Merger/Acquisition with Japan Regenerative Medicine. The deal was made on 04-Apr-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Japan Regenerative Medicine 04-Apr-2022 Merger/Acquisition Biotechnology
To view Metcela’s complete acquisitions history, request access »

Metcela FAQs

  • When was Metcela founded?

    Metcela was founded in 2016.

  • Where is Metcela headquartered?

    Metcela is headquartered in Kawasaki, Japan.

  • What is the size of Metcela?

    Metcela has 20 total employees.

  • What industry is Metcela in?

    Metcela’s primary industry is Drug Discovery.

  • Is Metcela a private or public company?

    Metcela is a Private company.

  • What is Metcela’s current revenue?

    The current revenue for Metcela is .

  • How much funding has Metcela raised over time?

    Metcela has raised $32.9M.

  • Who are Metcela’s investors?

    Cyberdyne, Reazon Capital, Reazon Holdings, TOHOKU University Venture Partners, and Alfresa Holdings are 5 of 22 investors who have invested in Metcela.

  • Who are Metcela’s competitors?

    Inovio Pharmaceuticals, Cellaion, WaVe Life Sciences, Skyhawk Therapeutics, and Cardurion are some of the 43 competitors of Metcela.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process